Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence Study of Dralitem vs Temodal in CNS Tumor Patients
NCT02343081Phase 4Completed
- Sponsor
- Monte Verde
- Start
- Jan 2012
- Primary completion
- Oct 2013
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of temozolomide in central nervous system cancer (2 arms), sponsored by Monte Verde. Primary endpoints: Maximum Plasma Concentration, Area Under the Curve to Last Timepoint and 1 more. Started Jan 2012; status: completed.
02
Drugs
temozolomide
03
Conditions
central nervous system cancer
Beyond the preview
Go deeper on NCT02343081.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02343081.